alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
|   | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

| /s/ Robert B.  McIntosh |
|-----------------------------------|
|                              |
| Name:                   | Robert B. McIntosh |
| Title:                            | President and Chief Executive Officer |
|                              |   |
|                              | (Principal Executive Officer) |
|                              |
| /s/ John J. Lennon                |
|                              |
| Name:                             | John J. Lennon |
| Title:                            | Chief Financial Officer |
|                              |   |
|                              | (Principal Financial Officer |
|                              | and Principal Accounting Officer) |

----
III 

117TH CONGRESS 

1ST SESSION S. RES. 334 

Memorializing those impacted by and lost to the COVID–19 virus. 

IN THE SENATE OF THE UNITED STATES 

AUGUST 3, 2021 

Ms. WARREN (for herself, Mr. MARKEY, and Mr. HEINRICH) submitted the 

following resolution; which was referred to the Committee on Health, 

Education, Labor, and Pensions 

RESOLUTION 

Memorializing those impacted by and lost to the COVID– 

19 virus. 

Whereas the first Monday in March is an appropriate day to 

be recognized as ‘‘COVID–19 Victims and Survivors Memorial Day’’; 

Whereas COVID–19 (SARS–CoV–2), a novel coronavirus, is 

a deadly illness caused by a virus that can transmit from 

person to person; 

Whereas, in 2020, COVID–19 began to spread throughout 

the world, creating a global pandemic that has had a catastrophic impact on human life, communities in the 

United States, and the United States economy; 

Whereas, in March 2020, communities in every State began 

to experience increased loss of life and families lost faVerDate Sep 11 2014 23:16 Aug 03, 2021 Jkt 019200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6300 E:\BILLS\SR334.IS SR334

pamtmann on DSKBC07HB2PROD with BILLS
2 

•SRES 334 IS 

thers, mothers, brothers, sisters, sons, daughters, and 

neighbors from the virus; 

Whereas, beginning in 2020, many across the United States 

were, and continue to be, personally impacted by 

COVID–19, including mourning their loved ones and 

neighbors or suffering from the unknown long-term 

health implications of the virus; 

Whereas, by the end of July 2021, there had been more than 

34,733,631 known cases of the virus in the United States 

and more than 600,000 people tragically lost their lives; 

Whereas COVID–19 has had a disproportionate impact on 

low-income communities and communities of color, with 

higher rates of infection and death, exacerbating inequities already prevalent in our systems that must addressed 

throughout the United States; 

Whereas public servants, frontline and essential workers, and 

health care professionals took selfless actions to protect 

their neighbors and communities, support struggling local 

economies, and find innovative ways to provide services; 

Whereas local, State, Tribal, and Federal Government entities provided critical support to businesses, communities, 

and the people of the United States in need; 

Whereas the COVID–19 pandemic continues to have an impact on the United States and countries around the 

world; and 

Whereas each life lost to COVID–19, each inequity and broken system brought to light, and each sacrifice made 

shall never be forgotten: Now, therefore, be it 

1 Resolved, That the Senate— 


pamtmann on DSKBC07HB2PROD with BILLS
3 

•SRES 334 IS 

1 (1) will memorialize those lost to the COVID– 

2 19 virus; 

3 (2) recognizes the suffering of those who con4 tracted the COVID–19 virus and survived but carry 

5 with them the unknown health side effects; and 

6 (3) expresses support for the designation of the 

7 first Monday in March as ‘‘COVID–19 Victims and 

8 Survivors Memorial Day’’. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS
Exhibit
32.2


Certification
of Principal Financial Officer
 Pursuant
to 18 U.S.C. § 1350,
 As
Adopted Pursuant to
 Section
906 of the Sarbanes-Oxley Act of 2002
 
 In
connection with the Quarterly Report of Reef Global Energy IV, L.P. (the
“Partnership”) on Form 10-Q for the quarter ended June 30, 2009 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I, L.
Mark Price, principal financial officer of Reef Global Energy IV, L.P., certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley
Act of 2002, that:
 
 (1)
              The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and
 
 (2)
              The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Partnership.
  Date:  August
      13, 2009
                /s/
      L. Mark PriceL.
      Mark Price
                  Chief
      Financial Officer
                  Reef
      Exploration, L.P.
                  (principal
      financial and accounting officer)
 This
certification accompanies the Report pursuant to § 906 of the Sarbanes-Oxley Act
of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act
of 2002, be deemed filed by the Partnership for purposes of § 18 of the
Securities Exchange Act of 1934, as amended.
 
 A signed
original of this written statement required by § 906 has been provided to the
Partnership and will be retained by the Partnership and furnished to the
Securities and Exchange Commission or its staff upon request.
Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Contact FDA

Contact FDA Home
          About FDA
          Contact FDA
          Get Email UpdatesContact FDA Get Email Updates
  
  	
    Share
    Post
    Linkedin

    Email
    PrintOur free e-mail alert service allows you to receive important FDA news and information as they become available. To sign up, please select the topics that interest you.

To subscribe, all you need is a valid e-mail address. Your e-mail will only be used to deliver the requested information or to give you access to your subscription preferences. Visit FDA’s privacy policy for more details.

Subscribe to FDA Email Notifications

                                                                                  Content current as of:
      09/09/2020Contact FDA
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the
Quarterly Report of Golden West Brewing Company, Inc. (the "Company") on Form
10-QSB for the period ended March 31, 2006, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John C. Power, President, Chief Executive Officer, Chief Financial Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                              
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                    
| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ John C. PowerJohn C. Power
President, Chief Executive Officer, Chief 
Financial Officer and Principal Accounting Officer
May 19, 2006
James Kevin MIXON v. STATE

CR-16-0994

Court of Criminal Appeals of Alabama.

February 2, 2018 Reh. denied March 2, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
_________________________________________ 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

September 10, 2007 Clifford W. Taylor,

 Chief Justice 

133095 Michael F. Cavanagh 

Elizabeth A. Weaver (69) Marilyn Kelly 

Maura D. Corrigan 

Robert P. Young, Jr. 

Stephen J. Markman, PEOPLE OF THE STATE OF MICHIGAN, Justices 

Plaintiff-Appellee, 

v SC: 133095 

 COA: 262698 

Jackson CC: 04-000690-FC 

WILLIAM JAMES HASTINGS,

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the motion for reconsideration of this Court's June 22, 2007 

order is considered, and it is DENIED, because it does not appear that the order was 

entered erroneously. 

Kelly, J., would grant reconsideration and, on reconsideration, would grant leave 

to appeal for the reasons stated in Justice Markman's previous statement in this case. 

MARKMAN , J., would grant reconsideration and, on reconsideration, would grant 

leave to appeal for the reasons set forth in his statement at People v Hastings, 478 Mich 

914 (2007). 

l0830 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

September 10, 2007 

 Clerk
James C. STALLWORTH, Appellant, v. STATE of Florida, Appellee.

No. 1D18-4312

District Court of Appeal of Florida, First District.

June 24, 2019

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
## In the Court of Appeals Second Appellate District of Texas at Fort Worth

___________________________ No. 02

- 24

- 00377

- CV

___________________________

Original Proceeding 153rd District Court of Tarrant County, Texas Trial Court No. 153

- 335243

- 22

Before Kerr, Bassel, and Wallach, JJ. Per Curiam Memorandum Opinion 

### I N RE 

### L INDA 

### M OLINA 

### , Relator2 MEMORANDUM OPINION
The court has considered relator’s petition for writ of mandamus , record, real
party in interest’s response, and relator’s rep ly and is of the opinion that relief should
be denied. Accordingly, relator’s petition for writ of mandamus is denied.

Per Curiam

Delivered : October 4, 2024
(a)
    
    Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;(b)
    
    Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;(c)
    
    Evaluated the effectiveness of the registrants disclosure controls
and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and(d)
    
    Disclosed in this report any change in the registrants internal
control over financial reporting that occurred during the registrants most
recent fiscal quarter (the registrants fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably likely to
materially affect, the registrants internal control over financial reporting;
and
  (a)
    
    All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrants ability to record, process, summarize
and report financial information; and(b)
    
    Any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrants internal control
over financial reporting.
 Date:  March 16, 2010
    /s/ Paul F. BolingPaul F. BolingChief Financial Officer
<PAGE>


                                                                    EXHIBIT 99.2

                            WEST POINTE BANCORP, INC.
                   CERTIFICATION OF PERIODIC FINANCIAL REPORT
                       PURSUANT TO 18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


            In connection with the annual report of West Pointe Bancorp, Inc.
(the "Company") on Form 10-K for the period ending December 31, 2002, as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, Bruce A. Bone, Executive Vice President and Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:

         (1)      The Report fully complies with the requirements of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)      The information contained in the Report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Company.


                                                   /s/ Bruce A. Bone
                                                   ---------------------------
                                                   Bruce A Bone
                                                   Executive Vice President and
                                                   Chief Financial Officer

March 26, 2003

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
<TABLE> <S> <C>

<ARTICLE>                5
<MULTIPLIER>             1,000

<S>                      <C>
<PERIOD-TYPE>                                  12-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-END>                                   DEC-31-1999
<CASH>                                                   0
<SECURITIES>                                       206,186
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                         0
<PP&E>                                                   0
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                     206,186
<CURRENT-LIABILITIES>                                    0
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                        200,000
<COMMON>                                             6,186
<OTHER-SE>                                               0
<TOTAL-LIABILITY-AND-EQUITY>                       206,186
<SALES>                                             17,155
<TOTAL-REVENUES>                                    17,155
<CGS>                                                    0
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                     17,155
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                 17,155
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                        17,155
<EPS-BASIC>                                              0
<EPS-DILUTED>                                            0


</TABLE>
Coy Vaughn BENTLEY, Appellant, v. Tuyen Tutu BENTLEY, Appellee.

Case No. 2D18-4200

District Court of Appeal of Florida, Second District.

Opinion filed May 24, 2019.

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
OFFICE OF THE CLERK

UNITED STATES DISTRICT COURT

Northern District of California

 CIVIL MINUTES

Date: January 17, 2018 Time: 22 minutes Judge: NATHANAEL M. 

COUSINS

Case No. 17-cv-00220-LHK Case Name: Federal Trade Commission v. Qualcomm 

Incorporated

Attorney for Qualcomm: Richard Stark 

Attorney for Non-Party Contract Manufacturers: Jason Lo 

Attorney for Non-Party Plaintiffs: Krysta Pachman 

Deputy Clerk: Lili Harrell FTR Time: 10:52am – 11:14am 

PROCEEDINGS

Telephonic Discovery Hearing held: 

Re: Dkt. [485] Court (1) set new deadline for completion of Contract Manufacturer document 

production to Qualcomm: Jan. 26, 2018, with privilege log due Feb. 2; (2) joint discovery update 

due Jan. 26; (3) Qualcomm motion for sanctions due Feb. 2, CM opposition due Feb. 9, and 

hearing Feb. 14 1:00 pm in San Jose Courtroom 7; no reply without further leave of court.

Re: Dkt [484] (motion to extend time for production)

Court RECOMMENDS to trial judge, Hon. Lucy Koh, that she grant in part (extending deadline 

for production to 1/26) and otherwise DENY Contract Manufacturer's motion to extend time for 

production, for the reasons stated on the record.

Case 5:17-cv-00220-LHK Document 493 Filed 01/17/18 Page 1 of 1
Exhibit 31.1

                                  CERTIFICATION

Elizabeth Plaza, certifies that:

1. I have reviewed this quarterly report on Form 10-QSB of Pharma-Bio Serv, Inc.
("Pharma-Bio Serv");

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of
Pharma-Bio Serv as of and for, the periods presented in this quarterly report;

4. Pharma-Bio Serv's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15(d)-15(e) for Pharma-Bio Serv and have:

      a. Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Pharma-Bio Serv, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being prepared;

      b. Evaluated the effectiveness of Pharma-Bio Serv's disclosure controls
and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and

      c. Disclosed in this report any change in Pharma-Bio Serv's internal
control over financial reporting that occurred during its most recent fiscal
quarter (Pharma-Bio Serv's fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially
affect, Pharma-Bio Serv's internal control over financial reporting.

5. Pharma-Bio Serv's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reportings to
Pharma-Bio Serv's auditors and the audit committee of Pharma-Bio Serv's board of
directors (or persons performing the equivalent functions):

      a. All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect Pharma-Bio Serv's ability to record, process,
summarize and report financial information; and

      b. Any fraud, whether or not material, that involves management or other
employees who have a significant role in Pharma-Bio Serv's internal controls
over financial reporting.

                         /s/ Elizabeth Plaza
                         -------------------
                         Elizabeth Plaza
                         Chief Executive Officer

June 14, 2006

                                       31